Company Encyclopedia
View More
name
Adma Biologics
ADMA.US
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin.
1.946 T
ADMA.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
A
BiotechnologyIndustry
Industry Ranking1/393
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreA
    • ROE63.17%A
    • Profit Margin42.87%A
    • Gross Margin56.34%B
  • Growth ScoreA
    • Revenue YoY27.62%A
    • Net Profit YoY207.41%A
    • Total Assets YoY45.59%A
    • Net Assets YoY85.94%A
  • Cash ScoreB
    • Cash Flow Margin233.26%C
    • OCF YoY27.62%A
  • Operating ScoreA
    • Turnover1.02A
  • Debt ScoreB
    • Gearing Ratio24.18%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    ADMA Biologics (ADMA): Assessing Valuation as Short Interest Declines and Market Sentiment Improves

    ADMA Biologics (ADMA) has seen a 5% drop in short interest, now at under 9%, below the biotech average of 14%. The share price has risen 22.4% in the past week and 26.6% over the past month. Analysts suggest the stock is undervalued, with a fair value of $27.25 compared to the current $19.21. The company is expected to see revenue growth from its FDA-approved yield enhancement process and increasing adoption of ASCENIV. However, challenges include a limited product portfolio and uncertainties in scaling up new manufacturing processes.

    Simplywall·
    US
    ADMA
    +1.98%
    Simplywall·
    US
    ADMA
    +1.98%

    High Growth Tech Stocks In The US Market November 2025

    The US market has seen mixed performance with modest rises in the Dow Jones and S&P 500, while the Nasdaq faced slight declines. Identifying high growth tech stocks requires considering innovation, market demand, and adaptability. Top high growth tech companies include ADMA Biologics, Palantir Technologies, Sanmina, Workday, Pelthos Therapeutics, Circle Internet Group, RenovoRx, Zscaler, Duos Technologies Group, and Procore Technologies. Notable mentions are CureVac, Arista Networks, and VTEX, each showing significant revenue and earnings growth.

    Simplywall·
    US
    ADMA
    +1.98%
    US
    CVAC
    -0.78%
    Simplywall·
    US
    ADMA
    +1.98%
    US
    CVAC
    -0.78%

    ADMA Biologics CEO Adam S. Grossman Reports Disposal of Common Shares

    Adam S. Grossman, President and CEO of ADMA Biologics Inc., has reported a disposal of common shares of the company. The full filing is available via EDGAR, the U.S. SEC's system.

    Reuters·
    US
    ADMA
    +1.98%
    Reuters·
    US
    ADMA
    +1.98%

    A Fresh Look at ADMA Biologics (ADMA) Valuation After Record Q3, Raised Guidance, and Operational Wins

    ADMA Biologics (ADMA) shares rose nearly 9% following a strong Q3 report, record revenue growth, and raised guidance for 2025 and 2026. Despite a year-to-date decline of 11%, long-term returns remain impressive at 395% over three years. Analysts set a fair value of $27.25, indicating potential undervaluation. However, the stock's price-to-earnings ratio aligns with industry averages, suggesting cautious optimism. Key operational breakthroughs could enhance profit margins, but reliance on few products poses risks. Investors are encouraged to explore further opportunities in the market.

    Simplywall·
    US
    ADMA
    +1.98%
    Simplywall·
    US
    ADMA
    +1.98%

    ADMA Biologics Inc. Reports Strong Q3 Earnings Call

    ADMA Biologics Inc. reported strong Q3 earnings with record revenue of $134.2 million, a 10% increase from the previous quarter and 12% year-over-year. The company raised its 2025 revenue guidance to $510 million and projects at least $630 million for 2026. ASCENIV utilization showed over 50% reduction in infection rates, and yield-enhanced production is expected to boost margins. Despite challenges in the IVIG market and a negative margin plasma sale, ADMA remains optimistic about its strategic initiatives and long-term growth prospects.

    Tip Ranks·
    US
    ADMA
    +1.98%
    Tip Ranks·
    US
    ADMA
    +1.98%
    © 2025 Longbridge｜Disclaimer